

## Interests Register

### Acute Coronary Syndromes Advisory Committee

**Publication Date: 18/11/2020**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Margaret Lally	ACS Committee chair	None					
Simon Corbett	ACS Committee Topic Adviser	Direct, non-financial	Member of Guidelines and Practice Committee, British Cardiovascular Society (BCS) (June 2016 onwards) – the committee reviews relevant cardiology practice guidelines (including those from NICE) and advises the BCS membership on their implementation and applicability. Non-pecuniary. Travel expenses paid by BCS as required.	2016	On application		Declare and participate

		Direct, non-financial	BCS/Royal College of Physicians (RCP) Regional Service Advisor (since 2010) – a liaison role between cardiologists and the BCS and RCP in the South Central region. Non-pecuniary. Travel expenses paid by BCS/RCP as required.	2010	On application	31/3/2018	Declare and participate
		Direct, non-financial	Independent Cardiologist member of Trial Steering Committee for the ongoing AVATAR trial sponsored by Imperial College London and funded by the British Heart Foundation and unrestricted educational grant from Medtronic (2015 onwards). This is a randomised controlled trial of different ablation techniques in atrial fibrillation. Non-pecuniary. Travel expenses paid by Imperial College as required.	2015	On application		Declare and participate

		Indirect, financial	<p>Local Investigator (UHSFT), RIPCORDER-2 trial. A randomised controlled UK-multi-centre trial evaluating routine 3 vessel-coronary pressure wire measurement vs routine angiographic guidance alone in patients with stable and acute coronary disease. Funded by an unrestricted educational grant from Boston Scientific. Principal Investigator, Prof Nick Curzen (Southampton)</p> <p>Local Investigator (UHSFT), T-Time trial. A randomised placebo-controlled trial of intra-coronary thrombolysis vs placebo in addition to usual primary PCI treatment for acute ST-elevation Myocardial Infarction. Funded by the Medical Research Council and the National Institute for Health Research. Principal Investigator, Prof Colin Berry (Glasgow)</p> <p>Local Investigator (UHSFT), Rapid-CT trial. A randomised UK-multi-centre trial evaluating the diagnostic utility and cost effectiveness of routine CT coronary angiography vs routine care in patients presenting to hospital with</p>	29.9.16	On application	Ongoing Due to finish June 2019	Declare and participate
				16.11.16	On application	28.9.18.	Declare and participate
				28.10.15	On application	Ongoing Due to finish June 2019	Declare and participate

			<p>suspected acute coronary syndrome. Funded by the National Institute for Health Research. Local Lead Investigator Prof Nick Curzen (Southampton)</p> <p>Local Investigator (UHSFT), Bioflow study. A post-marketing registry evaluating real world utilisation of the novel sirolimus-eluting Orsiro stent. A NIHR-portfolio study sponsored by Biotronik. Local Lead Investigator, Prof Michael Mahmoudi (Southampton).</p> <p>My role in all 4 of the research trials listed above is to recruit patients under my care at UHSFT who meet the relevant inclusion and exclusion criteria for each study in line with the principles enshrined in Good Clinical Practice. I receive no personal reimbursement for recruiting patients.</p>	2.3.17	On application	30.10.2018	Declare and participate
--	--	--	--	--------	----------------	------------	-------------------------

		Direct, non-financial	Independent Cardiologist on Trial Steering Committee (TSC) for PREDICT-VF study. The study is evaluating new algorithms for arrhythmia prediction in patients with Hypertrophic Cardiomyopathy. Funded by Medtronic, Sponsored by Imperial College London. Standard Class travel expenses to attend TSC meetings paid by Sponsor	20 March 2018	22 June 2018		Declare and participate
		Direct, non-financial	Local Investigator (UHSFT), RAPID-NSTEMI trial. This is a randomised controlled trial of immediate vs delayed angiography in non-ST-elevation myocardial infarction patients in whom an early interventional strategy is deemed appropriate. The trial is funded by the British Heart Foundation (grant code CS/17/1/32445). My role in this trial is to recruit patients under my care at UHSFT who meet the relevant inclusion and exclusion criteria for the study in line with the principles enshrined in Good Clinical Practice. I receive no personal reimbursement for recruiting patients. Local PI Prof N Curzen. Start date 11/3/2019.	11 March 2019	26 March 2019	Ongoing	Declare and participate

			Likely to be ongoing beyond end of the Guideline.				
		Indirect, non-financial	I attended a course entitled “Transcatheter Heart Valves – the Fundamentals” organised by Edwards LifeSciences in Nyon, Switzerland. Travel, accommodation and subsistence was provided by Edwards. This was an essential accreditation course to attend for all new transcatheter aortic valve implantation (TAVI) operators in UK and Europe (I have been selected to join the TAVI team in Southampton). TAVI is not a treatment for ACS, nor do Edwards make any products used in the treatment of ACS.	24-26 February 2020	21 July 2020	26 February 2020	Declare and participate.
Neil Swanson	ACS committee member - Cardiologist	Direct, financial	I have occasionally responded to market research surveys that relate to my opinions on the management of some acute chest pain conditions. In a year, I would estimate that this will be under £100. No payments/sponsorship come to me from any industry directly involved in the management of any cardiac conditions.	Ongoing	On application		Declare and participate. Not specific to the guideline scope.

		Indirect, financial	<p>Money is paid to our department from industry for the employment of clinical fellows, but I am not involved in that and do not know how much money is paid. I am not involved in the selection of such trainees.</p> <p>Money is paid to our research department for research trials from a variety of companies which have a commercial interest in the treatments for acute chest pain. None of this money is paid to me/spent by me.</p>	Ongoing	On application		Declare and participate
		Direct, non-financial	I am an unpaid member of the British Cardiovascular Society Guidelines committee, which I hope is not a conflict, but an attribute of value.	Ongoing	On application		Declare and participate
Christopher Cassidy	ACS committee member - cardiologist	Direct, financial	Consultancy fee and speaker fee from Boston Scientific relating to the subcutaneous defibrillator	July 2017	On application		<p>Declare and participate</p> <p>Subcutaneous defibrillators are not included in the scope for this guideline update</p>
		Direct, financial	Conference and travel fees paid by Menarini Pharmaceuticals to attend European Society of Cardiology Conference	August 2016	On application	August 2016	<p>Declare and participate.</p> <p>Travel, registration and accommodation only.</p>
		Direct, financial	Travel, registration and accommodation only support	June 2019	5 June 2019	June 2019	<p>Declare and participate.</p> <p>Travel, registration and</p>

			from Abbott to attend meeting on LVAD (left ventricular assist device) and advanced heart failure				accommodation only.
		Indirect, financial	Boston Scientific have provided financial support for a fellow in cardiac devices and heart failure in my department	June 2019	5 June 2019	June 2021	Declare and participate
Jaydeep Sarma	ACS committee member - cardiologist	Direct, non-financial	Medtronic provided my hospital with a grant to attend EuroPCR May 2018. This covered transport, registration and accommodation.	March 2018	On application	May 2018	Declare and participate.
Jaydeep Sarma	ACS committee member - cardiologist	Direct, financial	Abbott supported me to attend the Complete Revascularisation meeting in Amsterdam (March 2018).	March 2018	On application	March 2018	Declare and participate. Travel, registration and accommodation only.
Jaydeep Sarma	ACS committee member - cardiologist	Indirect, non-financial	British Cardiovascular Society Programme Committee member	June 2018	19 June 2018	June 2021	Declare and participate
		Direct, non-financial	Clinical Lead, Cardiovascular Domain, Health Innovation Manchester/ Manchester Academic Health Sciences Centre. Involves co-ordination between clinical and basic research in the Manchester area	August 2017	June 2018	Ongoing	Declare and participate

Jaydeep Sarma	ACS committee member - cardiologist	Direct, non-financial	Participating in a local pilot on rapid access angiography		October 2018		Declare and participate
Alex Sharp	ACS committee member - paramedic	Direct, non-financial	As cardiac lead I have been leading a project to define the minimum standard of paramedic ECG recognition within my Trust. This has included ACS as well as arrhythmias.	April 2017	On application	Ongoing	Declare and participate
		Direct, non-financial	I reviewed and updated my Trust's Acute Coronary Syndrome Clinical Guideline.	June 2017	On application	February 2018	Declare and participate
		Direct, non-financial	I am a reviewer for the British Paramedic Journal. This is a quarterly publication around paramedic care and unlikely to contain any papers specifically related to the guideline.  During the process of the NICE ACS guideline committee I will decline any ACS related papers and will inform the editor of this as well.	April 2017	July 2018	Ongoing	Declare and participate
Ewan Gittins	ACS committee lay member	Direct, non-financial	Member of the British Heart Foundation patient advisory group	January 2019	January 2019		Declare and participate
Farrah Al-Ghita	ACS Committee member,	None					

	pharmacist						
Alun Roebuck	ACS Committee member, nurse	None					
Lance Goodman	ACS Committee, lay member	None					
Muhammad Murad Khan	ACS Committee member, general practitioner	Indirect, Non-financial	Cardiology clinical lead for my Primary Care Network piloting community cardiology model, looking at heart failure patients with diabetes and the project is being funded by AstraZeneca. AstraZeneca paying for pharmacist clinical time and data analysis by a third party, the results will be forwarded to me and I will have the ultimate clinical decision role but no personal financial gain from this project. The results of this pilot will be presented to CCG and may be published if promising.	September 2020	21 July 2020	September 2021	Declare and participate

#### **GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.